

## Management of VHL Renal Tumors

Peter A. Pinto, M. D.


Urologic Oncology Branch  
National Cancer Institute  
Bethesda, Maryland

10<sup>th</sup> International VHL Medical Conference  
January 28, 2012




## VHL Clinical Features


- Tumors develop in:
  - Both Kidneys
  - Adrenal Glands
  - Pancreas
  - Brain or Spine
  - Eyes
  - Inner Ears



## Clear Cell Renal Carcinoma von Hippel Lindau (VHL)



## VHL: Clear Cell RCC



## Renal Cell Carcinoma

- T1  $\leq 7$  cm
  - T1a:  $\leq 4$  cm
  - T1b: 4-7 cm
- T2 Tumor  $> 7$  cm
- T3 Tumor invades outside the kidney
  - T3a: peri-renal sinus, fat, adrenal
  - T3b: renal vein, vena cava
- T4 Tumor invades beyond Gerota's Fascia


## RCC Tumor Size and Survival

Tumor Size (cm)	5 Year Survival
$\leq 2.5$	100 %
2.5- 4.9	83 %
5.0- 7.4	61 %
7.5- 10.	51 %

J Urology 155: 1196, 1996  
JSO 54: 163, 1993  
J Urology 152: 1389, 1994

JOS 59: 186, 1995  
J Urology 154: 901, 1995  
JSO 64: 295, 1997

## Management of Renal Carcinoma in VHL



### "3 cm rule"

- Delay surgery until diameter of largest renal tumor = 3 cm
- Active surveillance

Surgery = nephron sparing enucleation

## Inherited Forms of RCC

1. Von Hippel Lindau  
Clear Cell
2. Hereditary Papillary Renal Carcinoma  
Papillary Type 1
3. Birt Hogg Dubé:  
Chromophobe/Oncocytoma/Clear Cell
4. Hereditary Leiomyomatosis RCC  
Papillary Type 2

## Partial Nephrectomy

- Established technique
- Tumors  $\leq 4$  cm
  - Compared to Radical Nx, No difference in:
    - Disease specific survival
    - Tumor recurrence

Licht MR, Novick AC. Nephron sparing surgery for renal cell carcinoma. J Urol 1993



## Chronic Renal Insufficiency

- Compared to radical nephrectomy, nephron sparing surgery decreases risk of developing renal insufficiency

Hwang et al. Lancet Oncol 7: 735-40; 2006

Lau et al. Mayo Clin Proc 75: 1236-42; 2000



## Chronic Renal Insufficiency


- Independent predictor of morbidity from cardiovascular and non-cardiovascular events
- 26% of patients with SRM's and normal serum Cr present with renal insufficiency (GFR  $< 60$  ml/min)

Go et al. NEJM 351: 1296-305; 2004

Hwang et al. Lancet Oncol 7: 735-40; 2006



## T1a Treatment: Partial Nephrectomy Enucleation?




- SRM  $\leq 4$  cm
- Cancer Specific Survival
  - 90 – 95%
- Local Recurrence
  - 4 – 6%




### Tumor Enucleation



### Tumor Enucleation




### Pre-operative CT




40 y.o. male  
Cr Cl = 157 ml/min  
 $S_{cr} = 0.9$  mg/dl


### Intra-op before resection



### Intra-op after resection



### Post-operative CT



Cr Cl = 128 ml/min  
 $S_{cr} = 1.0$  mg/dl

## 3 cm Rule

- No one has developed RCC metastasis when following this rule

## What happens when new tumors develop?

### Feasibility and Outcomes of Repeat Partial Nephrectomy

Aaron Johnson,\* Sunil Sudarshan,\* Jack Liu, W. Marston Linehan, Peter A. Pinto and Gennady Bratslavsky†

From the Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland

0022-5347/09/1901-0089\$08.00/0 Vol. 190, 89-93, July 2009  
THE JOURNAL OF UROLOGY® Printed in U.S.A.  
Copyright © 2009 by AMERICAN UROLOGICAL ASSOCIATION DOI:10.1016/j.juro.2009.03.036


### Salvage Partial Nephrectomy for Hereditary Renal Cancer: Feasibility and Outcomes

Gennady Bratslavsky,\* Jack J. Liu, Aaron D. Johnson, Sunil Sudarshan, Peter L. Choyke, W. Marston Linehan and Peter A. Pinto

From the Urologic Oncology Branch and Molecular Imaging Program (PLC), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland

0022-5347/09/1791-0067\$08.00/0 Vol. 179, 67-70, January 2009  
THE JOURNAL OF UROLOGY® Printed in U.S.A.  
Copyright © 2009 by AMERICAN UROLOGICAL ASSOCIATION DOI:10.1016/j.juro.2007.09.196

## Evolving Surgical Therapies for RCC



## Surgical Techniques for NSS


- Comfort level and experience dictates partial nephrectomy approach



## Minimally Invasive NSS

- Emulates open surgery
- Surgical tools are the same for open and minimally invasive NSS
  - Vascular clamps
  - Sutures and Hemostatic aids
  - Scissors, Penfield and right angle dissectors
  - Intra-operative Ultrasound


## Laparoscopic Partial Nephrectomy



## Retroperitoneal Approach



## Laparoscopic Partial Nephrectomy



## Laparoscopic Partial Nephrectomy



## Laparoscopic Partial Nephrectomy



## Minimally Invasive Partial Nephrectomy: Can Robotics Help?

- Improvement in technology and skill level for laparoscopic surgeons
- Role of laparoscopy in extirpative and reconstructive urologic surgery is expanding
- Lap NSS can be difficult to teach and reproduce
- Difficult for open trained surgeons to perform
  - Similar to: open → laparoscopic → robotic prostatectomy

## Evolution of Surgery

- Open Surgery
  - Full Range of Motion; Full 3-D Visualization
  - Large Incision; Long Recovery due to surgical morbidity

## Evolution of Surgery

- **Laparoscopic Surgery**
  - Minimally Invasive; Reduced LOS & morbidity
  - Vision: 2-D; 4-5x Magnification
  - Instruments: 4 Degrees of Motion; Rigid Instruments; Opposite Movement
  - Result: Long Learning Curve; Difficult for Complex / Reconstructive Surgery




## Evolution of Surgery

- **Robotic Surgery**
  - Vision: 3-D; 10x Magnification
  - Instruments: 7 Degrees of Motion; Replicated Movement – "Mimics Open Surgical Technique"
  - Instruments: Full Control of Camera and Arms
  - Result: Shorter Learning Curve; More Complex Surgery; Benefits of MIS to Broader Base of Patient




## daVinci Surgical System



Novakovic, K and Pinto, P. *CANCER: Principles and Practice of Oncology*, 8th ed.




## daVinci Surgical System



Novakovic, K and Pinto, P. *CANCER: Principles and Practice of Oncology*, 8th ed.



## Port Access for the Robotic Arms



Novakovic, K and Pinto, P. *CANCER: Principles and Practice of Oncology*, 8th ed.



## Robotic Assisted Partial Nephrectomy






## Robotic Assisted Partial Nephrectomy



## Robotic Partial Nephrectomy



available at www.sciencedirect.com  
journal homepage: www.europeanurology.com

**EAU**  
European Association of Urology

**Surgery in Motion**

**Robotic Partial Nephrectomy for Complex Renal Tumors:  
Surgical Technique**

Craig G. Rogers<sup>1</sup>\*, Amar Singh, Adam M. Blatt, W. Marston Linehan, Peter A. Pinto<sup>1</sup>  
<sup>1</sup>Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

**Table 3 - Results for individual patients undergoing robotic partial nephrectomy**

No.	No. of tumors	Tumor location	Tumor size, cm	Operative time, min	Warm ischemia time, min	Mean blood loss, mL	Pathology
1	1	Hilar	2.6	185	29	330	Clear cell RCC, Fuhrman 2
2	3	Endo, LP	2.6	214	24	330	Hybrid oncocytic tumor <sup>2</sup>
3	4	MP (L)	1.5, 5.8	—	—	—	—
4	1	LP (L)	2.3	204	45 <sup>3</sup>	450	Chromophobe RCC
5	1	LP (R)	2.5, 1.2, 1.3	—	—	—	—
6	1	Hilar	6.4	185	33	300	Hybrid oncocytic tumor
7	1	Hilar, endo	2.9	200	36	150	Clear cell RCC, Fuhrman 2
8	1	Hilar	4.0	180	24	200	Clear cell RCC, Fuhrman 2
9	2	Endo	3.0	191	25	340	Oncocytoma
10	1	LP	6.8	—	—	—	Angiosarcoma
11	1	Hilar/LP, endo	4.5	195	31	200	Chromophobe RCC

LP = upper pole; LP = lower pole; MP = midpole; endo = endophytic; RCC = renal cell carcinoma.  
<sup>1</sup> Tumor measured self-clamp.  
<sup>2</sup> Same histologic subtype for all renal tumors resected.  
<sup>3</sup> Total warm ischemia time for resection of all tumors.



## Surgical Techniques for NSS


- Open
- Laparoscopic
  - Pure lap

Regardless of technique, goal is to spare nephrons

- Robotic assisted
  - da Vinci surgical system



## Evolving Surgical Therapies for RCC



## RFA Treatment of RCC

- Percutaneous, outpatient procedure
- Conscious sedation and local anesthesia
- U/S or CT imaging to place needle
- 15- 18 gauge needle with insulated shaft
- Two 10 minute treatments per tumor
- Monitor impedance or temperature
- Cauterize needle tract, avoid bleeding and prevent tumor seeding

## NCI Phase II Trial

- Hereditary kidney cancer
  - Solid tumors, <3 cm
  - Tumor growth over 1 year
  - Creatinine  $\leq 1.7$  or clearance  $> 60$  ml/ min
- Radio frequency ablation technique
  - 200 watt device
  - Percutaneous or laparoscopic approach
  - CT or US guidance
  - 2 to 4 heating cycles at 12 minutes each
- Outcomes
  - Radiographic assessment (size and enhancement)
  - Renal function



## CONCLUSION

- VHL Renal Tumors are clear cell RCC
- "3 cm rule" balances need for dialysis and tumor spread
- Partial nephrectomy / ablation but avoid radical nephrectomy when possible, even after prior renal surgery



## CONCLUSION

Laparoscopic



Robotic



Open



## Acknowledgements



Urologic Oncology Branch, NCI



## NIH Clinical Center

